Skip to content

NeuBase Therapeutics, Inc.: 10-Q filed 2011-08-15

What NeuBase Therapeutics, Inc. reported in its quarterly report filed 2011-08-15 (fiscal Q3 2011): 27 published measures, 86 facts as tagged in accession 0001387131-11-001669.

This filing

Form
10-Q (quarterly report)
Filed
2011-08-15
Fiscal period
fiscal Q3 2011
Accession
0001387131-11-001669 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NeuBase Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-06-301,652,489USD
At 2010-09-301,412,025USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2011-06-305,186,754USD
At 2010-09-301,794,482USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-06-30-3,534,265USD
At 2010-09-30-382,457USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-3,137,548USD91
2010-10-01 to 2011-06-30-3,743,236USD273
2007-10-01 to 2011-06-30-4,088,481USD1369
2009-10-01 to 2010-09-30494,377USD365
2010-04-01 to 2010-06-30-176,605USD91
2009-10-01 to 2010-06-30-497,161USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2010-10-01 to 2011-06-30-595,775USD273
2007-10-01 to 2011-06-30-2,052,219USD1369
2009-10-01 to 2010-06-30-366,171USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2007-10-01 to 2011-06-3025,018USD1369

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2010-10-01 to 2011-06-30981,399USD273
2007-10-01 to 2011-06-302,570,000USD1369
2009-10-01 to 2010-06-30620,368USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2010-10-01 to 2011-06-3070,500USD273
2007-10-01 to 2011-06-30163,482USD1369

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2011-06-30-21,628,748USD
At 2010-09-30-21,628,748USD

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-0.08USD/shares91
2010-10-01 to 2011-06-30-0.1USD/shares273
2010-04-01 to 2010-06-300USD/shares91
2009-10-01 to 2010-06-30-0.02USD/shares273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-06-3020,416USD
At 2010-09-3024,168USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2010-10-01 to 2011-06-3035,925USD273
2007-10-01 to 2011-06-30667,326USD1369

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-301,531USD91
2010-10-01 to 2011-06-30-867,769USD273
2007-10-01 to 2011-06-30-3,482,885USD1369
2010-04-01 to 2010-06-30-354,593USD91
2009-10-01 to 2010-06-30-686,943USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-06-30910,392USD
At 2010-09-30607,450USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2011-04-01 to 2011-06-3084USD91
2010-10-01 to 2011-06-302,433USD273
2007-10-01 to 2011-06-3049,723USD1369
2010-04-01 to 2010-06-302,495USD91
2009-10-01 to 2010-06-3019,288USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-06-30325,055USD
At 2010-09-30406,826USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-04-01 to 2011-06-30301,531USD91
2010-10-01 to 2011-06-30867,769USD273
2007-10-01 to 2011-06-303,482,885USD1369
2010-04-01 to 2010-06-30354,593USD91
2009-10-01 to 2010-06-30686,943USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-04-01 to 2011-06-3073,144USD91
2010-10-01 to 2011-06-30350,407USD273
2007-10-01 to 2011-06-30628,958USD1369
2010-04-01 to 2010-06-3014,497USD91
2009-10-01 to 2010-06-3073,399USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-06-3035,452,580shares
At 2010-09-3035,452,580shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2011-06-3022,178,436USD
At 2010-09-3021,587,433USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2011-06-30-3,534,265USD
At 2010-09-30-382,457USD
At 2009-09-30612,685USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-3,137,548USD91
2010-10-01 to 2011-06-30-3,743,236USD273
2007-10-01 to 2011-06-30-4,766,894USD1369
2010-04-01 to 2010-06-30-176,605USD91
2009-10-01 to 2010-06-30-497,161USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-04-01 to 2011-06-30228,387USD91
2010-10-01 to 2011-06-30517,362USD273
2007-10-01 to 2011-06-302,853,927USD1369
2010-04-01 to 2010-06-30340,096USD91
2009-10-01 to 2010-06-30613,544USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2010-10-01 to 2011-06-303,752USD273
2007-10-01 to 2011-06-304,602USD1369

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2010-10-01 to 2011-06-3058,726USD273
2007-10-01 to 2011-06-3078,319USD1369

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2011-04-01 to 2011-06-3050USD91
2010-10-01 to 2011-06-301,662USD273
2007-10-01 to 2011-06-30159,824USD1369
2010-04-01 to 2010-06-3039,514USD91
2009-10-01 to 2010-06-3068,101USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-2,836,017USD91
2010-10-01 to 2011-06-30-2,875,467USD273
2007-10-01 to 2011-06-30-1,284,009USD1369
2010-04-01 to 2010-06-30177,988USD91
2009-10-01 to 2010-06-30189,782USD273

Inspect the source

Entity
NeuBase Therapeutics, Inc. / CIK 0001173281
Captured
SEC response SHA-256
0e0882fa147fcb0a3e5f3af54573abe947d9ade4d42095debd16c2d62da36e79

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001173281.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))